MPI, New York Node | Associate Professor, NYU Grossman School of Medicine

Dr. Jennifer McNeely Jennifer McNeely, MD, MS is Associate Professor at NYU Grossman School of Medicine. She is MPI of the New York Node of the NIDA Clinical Trials Network, and Co-Director of the Section on Tobacco, Alcohol, and Drug Use in the Department of Population Health. She is a general internist specialized in Addiction Medicine, and practices at Bellevue Hospital. 

As a clinician investigator, Dr. McNeely’s research centers on utilizing health care contacts to address unhealthy substance use. Dr. McNeely has led or co-led multiple CTN trials in primary care settings, including studies on screening tools (CTN-0059), their implementation in electronic health records (CTN-0062), interventions for risky opioid use (CTN-0101), and collaborative care for polysubstance use (CTN-0139). She co-chairs the Implementation Outcomes working group of the CTN Translation and Implementation Special Interest Group.

MPI, New York Node | Professor, Columbia University Irving Medical Center

Dr. Aimee Campbell is an MPI of the New York Node of the NIDA CTN and has been involved with the network since 2003. She is a Professor of Clinical Psychiatric Social Work at Columbia University Irving Medical Center and a Research Scientist at the New York State Psychiatric Institute.

Her work focuses on the development and testing of interventions for substance use disorders and co-occurring health and mental health disorders with an emphasis on increasing adoption and implementation of best practice treatments. She specializes in implementation science, digital health, and pragmatic trials in real-world settings. Dr. Campbell has co-led several national CTN studies, including CTN-0070 (on confidentiality barriers), CTN-0044A2 (web-based behavioral treatment for Tribal communities), and CTN-0096 (implementation strategies to integrate medications for OUD within Tribal communities). Her contributions as a co-investigator and project director on CTN-0044 helped support the development of reSET®, the first FDA-authorized prescription digital therapeutic for SUD.

She was a co-chair of the CTN Gender Special Interest Group (2012-2025) and serves on the CTN Publications Committee. Dr. Campbell currently co-leads CTN-0155 (Project BISTRO; testing low-threshold buprenorphine in syringe service programs).

MPI, New York Node | Professor of Psychiatry, Columbia University

Dr. Edward Nunes is an MPI of the New York Node of the NIDA CTN and has been a leader in the network since its inception in 1999. He is a Professor of Psychiatry at Columbia University and an expert in treatments for substance use disorders and comorbid psychiatric conditions.

He has led several landmark CTN trials, including CTN-0044 (web-based behavioral therapy), CTN-0051 (X:BOT, comparing extended-release naltrexone and buprenorphine), and CTN-0100 (interventions to improve MOUD retention). His research has informed clinical guidelines and expanded access to evidence-based addiction treatment in both community and medical settings.

Dr. Nunes serves on the CTN Steering and Research Development Committees and has mentored numerous early-career investigators through NIH training programs. He has authored over 200 peer-reviewed publications and continues to drive innovation in addiction research and care delivery.